Table 3.
The use of immunosuppressive therapy related to age in the CHE-IBD cohort at February 28, 2020 (n = 1428), and February 28, 2021 (n = 1453), in absolute numbers and percentage of the cohort
| Biologic agents | Thiopurines | Budesonide | Prednis(lo)ne | Methotrexatre | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 2020 n (% of cohort) | 2021 n (% of cohort) | 2020 n (% of cohort) | 2021 n (% of cohort) | 2020 n (% of cohort) | 2021 n (% of cohort) | 2020 n (% of cohort) | 2021 n (% of cohort) | 2020 n (% of cohort) | 2021 n (% of cohort) |
| 0–18 | 17 (1.2) | 20 (1.4) | 26 (1.8) | 27 (1.9) | 0 (0) | 0 (0) | 0 (0) | 1 (0.1) | 3 (0.2) | 2 (0.1) |
| 18–24 | 34 (2.4) | 41 (2.8) | 48 (3.4) | 38 (2.6) | 5 (0.4) | 3 (0.2) | 1 (0.1) | 6 (0.4) | 0 (0) | 0 (0) |
| 25–39 | 85 (6.0) | 111 (7.6) | 101 (7.1) | 106 (7.3) | 9 (0.6) | 14 (1.0) | 9 (0.6) | 9 (0.6) | 0 (0) | 0 (0) |
| 40–49 | 48 (3.4) | 54 (3.7) | 56 (3.9) | 53 (3.6) | 12 (0.8) | 10 (0.7) | 8 (0.6) | 6 (0.4) | 1 (0.1) | 1 (0.1) |
| 50–59 | 34 (2.4) | 44 (3.0) | 55 (3.9) | 54 (3.7) | 11 (0.8) | 15 (1.0) | 12 (0.8) | 8 (0.6) | 2 (0.1) | 3 (0.2) |
| 60–69 | 22 (1.5) | 26 (1.8) | 32 (2.2) | 34 (2.3) | 22 (1.5) | 17 (1.2) | 9 (0.6) | 6 (0.4) | 0 (0) | 0 (0) |
| 70–79 | 10 (0.7) | 12 (0.8) | 22 (1.5) | 30 (2.1) | 12 (0.8) | 14 (1.0) | 10 (0.7) | 6 (0.4) | 2 (0.1) | 2 (0.1) |
| ≥ 80 | 0 (0) | 3 (0.2) | 6 (0.4) | 5 (0.3) | 7 (0.5) | 7 (0.5) | 2 (0.1) | 2 (0.1) | 0 (0) | 1 (0.1) |
n number of patients at that timepoint